MedPath

Recombinant Human Coagulation Factor Ⅷ

Generic Name
Recombinant Human Coagulation Factor Ⅷ

Overview

No overview information available.

Background

No background information available.

Indication

用于血浆凝血因子Ⅷ(FⅧ)缺乏的甲型血友病(罕见病)治疗。在纠正或预防出血、急诊或择期手术中,本品起到暂时代替缺失的凝血因子的作用。

Associated Conditions

No associated conditions information available.

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/03/07
Phase 4
Recruiting
Runhui WU
2022/10/17
Phase 3
Recruiting
2022/02/22
Phase 1
Completed
Jiangsu Gensciences lnc.
2021/04/29
Phase 1
Completed
Jiangsu Gensciences lnc.
2018/11/20
N/A
UNKNOWN
Kaifeng Pharmaceutical (Group) Co., Ltd.
2016/10/21
N/A
Active, not recruiting
2015/06/26
Phase 1
Completed
2014/12/11
Phase 4
UNKNOWN
St. James's Hospital, Ireland
2014/12/03
Phase 3
Completed
2014/11/04
Not Applicable
UNKNOWN
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.
© Copyright 2025. All Rights Reserved by MedPath